Feil Family Brain & Mind Research Institute

You are here

Vascular dysfunction-The disregarded partner of Alzheimer's disease.

TitleVascular dysfunction-The disregarded partner of Alzheimer's disease.
Publication TypeJournal Article
Year of Publication2019
AuthorsSweeney MD, Montagne A, Sagare AP, Nation DA, Schneider LS, Chui HC, Harrington MG, Pa J, Law M, Wang DJJ, Jacobs RE, Doubal FN, Ramirez J, Black SE, Nedergaard M, Benveniste H, Dichgans M, Iadecola C, Love S, Bath PM, Markus HS, Salman RA, Allan SM, Quinn TJ, Kalaria RN, Werring DJ, Carare RO, Touyz RM, Williams SCR, Moskowitz MA, Katusic ZS, Lutz SE, Lazarov O, Minshall RD, Rehman J, Davis TP, Wellington CL, González HM, Yuan C, Lockhart SN, Hughes TM, Chen CLH, Sachdev P, O'Brien JT, Skoog I, Pantoni L, Gustafson DR, Biessels GJan, Wallin A, Smith EE, Mok V, Wong A, Passmore P, Barkof F, Muller M, Breteler MMB, Román GC, Hamel E, Seshadri S, Gottesman RF, van Buchem MA, Arvanitakis Z, Schneider JA, Drewes LR, Hachinski V, Finch CE, Toga AW, Wardlaw JM, Zlokovic BV
JournalAlzheimers Dement
Volume15
Issue1
Pagination158-167
Date Published2019 Jan
ISSN1552-5279
Abstract

Increasing evidence recognizes Alzheimer's disease (AD) as a multifactorial and heterogeneous disease with multiple contributors to its pathophysiology, including vascular dysfunction. The recently updated AD Research Framework put forth by the National Institute on Aging-Alzheimer's Association describes a biomarker-based pathologic definition of AD focused on amyloid, tau, and neuronal injury. In response to this article, here we first discussed evidence that vascular dysfunction is an important early event in AD pathophysiology. Next, we examined various imaging sequences that could be easily implemented to evaluate different types of vascular dysfunction associated with, and/or contributing to, AD pathophysiology, including changes in blood-brain barrier integrity and cerebral blood flow. Vascular imaging biomarkers of small vessel disease of the brain, which is responsible for >50% of dementia worldwide, including AD, are already established, well characterized, and easy to recognize. We suggest that these vascular biomarkers should be incorporated into the AD Research Framework to gain a better understanding of AD pathophysiology and aid in treatment efforts.

DOI10.1016/j.jalz.2018.07.222
Alternate JournalAlzheimers Dement
PubMed ID30642436
PubMed Central IDPMC6338083
Grant ListP41 EB015922 / EB / NIBIB NIH HHS / United States
R01 AG023084 / AG / NIA NIH HHS / United States
P50 AG005142 / AG / NIA NIH HHS / United States
R01 AG039452 / AG / NIA NIH HHS / United States
R01 NS037853 / NS / NINDS NIH HHS / United States
R01 NS100447 / NS / NINDS NIH HHS / United States
R01 NS034179 / NS / NINDS NIH HHS / United States
R01 NS034467 / NS / NINDS NIH HHS / United States
R01 NS095441 / NS / NINDS NIH HHS / United States
RF1 AG054548 / AG / NIA NIH HHS / United States
R01 NS090904 / NS / NINDS NIH HHS / United States
R01 NS100459 / NS / NINDS NIH HHS / United States
R01 AG058969 / AG / NIA NIH HHS / United States
R01 AG054069 / AG / NIA NIH HHS / United States
R37 NS089323 / NS / NINDS NIH HHS / United States
P01 AG052350 / AG / NIA NIH HHS / United States